Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Wins Approval for Liquid Kenketu Glovenin-I 10%; Overseas-Derived Version Already Launched
Takeda Pharmaceutical said on February 10 that it has received Japanese regulatory approval for Kenketu Glovenin-I 10% for IV Injection (polyethylene glycol-treated human immunoglobulin), a plasma-derived therapy. The product is an improved liquid formulation of the existing freeze-dried Kenketu Glovenin-I…
To read the full story
Related Article
- Takeda Rolls Out Higher-Concentration Kenketu Glovenin-I 10%
July 7, 2026
- Takeda to Shift Immunoglobulin Production to 10% Formulation
June 29, 2026
- Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
- Takeda Mulls Boost in Imports amid Kenketu Glovenin-I Suspension
November 5, 2025
- Takeda Halts Shipments of Kenketu Glovenin-I to Review Narita Plant Process
November 5, 2025
- Takeda Files Liquid Formulation of IVIg Therapy in Japan
February 17, 2025
BUSINESS
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Chugai Files Tecentriq for Colon Cancer Adjuvant Therapy in Japan
August 17, 2026
- Enflonsia Filed for High-Risk Children in 2nd RSV Season in Japan: MSD
August 17, 2026
- Healios to File MultiStem in Japan Without Waiting for PIII Results: CEO
August 17, 2026
- Taiho’s Zipalertinib Hits Primary Goal in 1st Line NSCLC Trial
August 17, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…